August 26, 2013Cytometry Part B Clinical Cytometry
Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein phosphorylation to assess P2Y12-inhibition after ticagrelor intake
Why the study?
Does the new ELISA-based VASP assay provide comparable platelet reactivity index results to the flow cytometric assay after ticagrelor intake in healthy volunteers?
Population
6 healthy volunteers
Comparison
ELISA-based vasodilator-associated stimulated… vs Flow cytometric VASP assay
Design
Cohort
Follow-up
2-6 hours
Authors
Discussion
Loading...
Member takes
Implication
ELISA-based VASP assay correlates well with flow cytometry but yields lower PRI; leaves open need for method-specific thresholds before clinical use.
Structured PICO
Does the new ELISA-based VASP assay provide comparable platelet reactivity index results to the flow cytometric assay after ticagrelor intake in healthy volunteers?
P
Population
6 healthy volunteers
I
Intervention
ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay after a single 180 mg loading dose of ticagrelor
C
Comparator
Flow cytometric VASP assay
O
Outcome
Platelet reactivity index (PRI) comparison between assayssurrogate
The new ELISA-based VASP assay correlates well with flow cytometry for assessing ticagrelor-induced platelet inhibition but yields lower PRI levels, especially when PRI falls below 20%.
Cite This Study
Hobl et al. (2013) studied this question.